Abstracts OBJECTIVES: Updated risk equations are available for predicting outcome in people with type 2 diabetes (T2D): the UKPDS Outcomes Model (UKPDS 68). It is important to assess the validity of applying risk equations to populations other than those from which they were derived. The objective was to evaluate how well the UKPDS-68 equations predicted vascular morbidity and mortality in real-life data from Cardiff, UK, and compare estimates with the previous UKPDS Risk Engine equations (UKPDS-RE [from UKPDS publications 56 and 60]). METHODS: The equations were incorporated into a stochastic simulation model that estimated the incidence and prevalence of complications (DiabForecaster). Predicted results from the model were compared with population data from Cardiff for coronary heart disease (CHD), stroke and all cause mortality. The annual incidence of newly diagnosed T2D, baseline modifiable risk factors and demographic profiles were matched to the Cardiff data. RESULTS: Internal validation, using a baseline cohort matched to the UKPDS study, demonstrated that the model predicted 12-year cumulative incidence in line with previous UKPDS publications. Real life and predicted event rates for CHD were: 116, 153 and 137 events/1000 T2D patients/yr for the Cardiff data, UKPDS-RE and UKPDS-68, respectively. For stroke: 178, 153 and 128 events/1000 T2D patients/yr, respectively. For all cause mortality: 418, 430, and 475 events/1000 T2D patients/yr, respectively. CONCLUSIONS: All UKPDS equations demonstrated internal validity when compared with published UKPDS data, however both UKPDS-RE and UKPDS-68 equations over predicted the incidence of CHD and mortality and under predicted stroke. While all endpoints predicted were reasonably concordant with observational data discrepancies between UKPDS-68 and UKPDS-RE are worthy of further investigation.
1 Eli Lilly and Company, Indianapolis, IN, USA, 2 M-TAG Limited, a unit of IMS, London, UK OBJECTIVES: To survey healthcare professional (HCP) recommendations and patient practices regarding blood glucose selfmonitoring among type-2 diabetic (T2D) patients receiving pharmacotherapy and to investigate the potential impact of a new incretin mimetic therapy (IMT). METHODS: HCPs in the UK (N = 50) were interviewed using structured questionnaire methodology. The survey investigated recommended and actual frequencies of self-monitoring according to type of therapy (oral therapy alone [oral(s)], insulin ± oral therapy) and phase of treatment (initiation, steady state), and investigated self-monitoring recommendations for the IMT. Additionally, patients with T2D (N = 26) were questioned by structured telephone interview. RESULTS: The average frequency of self-monitoring recommended by HCPs was 3-4 times higher for patients on insulin ± oral than for those on oral(s) (p < 0.001). Regarding actual selfmonitoring frequencies at steady state, 50% of HCPs believed patients on insulin ± oral tested less than recommended. Fewer HCPs (39%) believed that patients on oral(s) self-monitored less than recommended (p ≤ 0.05). In contrast, most patients (~70%) believed themselves compliant, regardless of therapy type. Most HCPs (~98%) would recommend that patients on the IMT selfmonitor less than or the same as if they were on insulin ± oral, with the majority indicating that patients on IMT monitor less frequently. In comparison, most HCPs (>84%) would recommend that patients on IMT self-monitor the same as or more than if they were on oral(s), with the majority indicating that patients on IMT monitor the same as oral(s) only at steady state. CONCLUSIONS: HCPs recommend significantly more frequent self-monitoring for patients on insulin ± oral than oral(s). HCPs perceive patients on oral(s) to be more compliant to self-monitoring than those on insulin ± oral. Overall, patients see themselves as more compliant than do HCPs. The HCP recommended frequency for self-monitoring with the new IMT would lie between the recommended frequencies for oral(s) and insulin ± oral, but more similar to oral(s) at steady state. 
PDB21 ANTIDIABETIC MEDI CATION PRESCRIBING TRENDS IN FRANCE: EVIDENCE FROM PRIMARY CARE PHYSICIANS

RESULTS:
A total of 14,281 unique diabetic patients were examined over the time period from 2001 to 2003. A unique drug therapy episode was defined as any use of medication or medication combination for at least 45 days. Among users of antidi-abetic agents, individuals had an average of 1.28 drug therapy episodes per calendar year. Univariate analyses revealed that between 2001 and 2003, monotherapy use of sulfonylurea decreased (p < 0.0001), while monotherapy use of metformin (p < 0.0001) and insulin (p = 0.0437) increased. Multivariate logistic regressions that compared prescription therapy episodes in 2003 to those in 2001 revealed that the influence of year on likelihood of using metformin or insulin (either alone or in combination with other medications) was positive and significant (p < 0.05). In contrast, the influence of year on the likelihood of using sulfonylurea monotherapy was negative and significant (p < 0.05). CONCLUSIONS: Antidiabetic medication prescribing patterns have changed in France in the early 21st century. In general, the trend has been away from sulfonylurea monotherapy and towards metformin and insulin monotherapy or combination therapy.
DIABETES-Methods and Concepts
PDB22 RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDY WITH PROPENSITY SCORE METHODS: CAN THEIR RESULTS CONVERGE?-A CASE STUDY IN ESTIMATING MARGINAL EFFECT OF INSULIN REGIMENS ON THE REDUCTION OF HEMOGLOBIN A1C AMONG PATIENTS WITH TYPE 2 DIABETES
Sun P, Liu C, Xu R Lilly Research Laboratories, Indianapolis, IN, USA Randomized controlled trials (RCT) and observational studies with propensity score methods (PSM) are the two common approaches to mimic counterfactual premises in estimating treatment effects. Although, in theory, correct exercises of either approach can reveal the similar truth, no empirical evidence has shown such convergence. OBJECTIVE: To examine whether similar studies using either approach can reach converging results of a treatment effect. METHODS: Two small 32-week crossover RCTs (n = 105 and 97; crossover at 16th weeks) and one large retrospective observational study with PSM (n = 4519) were conducted to examine and compare the marginal effect of insulin regimen (once-daily basal analog insulin-glargine vs. twice-daily basal and bolus analog insulin-lispro mix 75/25) on the reduction of hemoglobin A1c (HbA1c) among patients with type 2 diabetes. The differences in mean HbA1c reductions between two insulin regimens were estimated as the marginal effect for individual studies. RESULTS: Two RCTs showed that twice-daily basal and bolus analog insulin (lispro 75/25) had 0.4 and 0.6 more units of HbA1c reduction than once-daily basal analog insulin (glargine) respectively. Likewise, the retrospective observational study with PSM also found that twice-daily basal and bolus analog insulin (lispro 75/25) reduced 0.55 and 0.65 more units of HbA1c than once-daily basal analog insulin (glargine) at the end of 1st and 2nd post-baseline quarters respectively. CONCLUSIONS: Two RCTs and 1 observational study with PSM revealed that twice-daily short-acting analog insulin regimen (lispro 75/25) reduced more unit of HbA1c than oncedaily long-acting analog insulin regimen (glargine) did. This fact supports that correct exercises of RCTs and observational studies with PSM can reveal the similar level of treatment effect. To determine whether inducing correlation among triglyceride, HDL, and LDL levels in a pharmaceutical treatment Monte Carlo simulation affects parameters' means and variances; proportion with all parameters controlled; and summary statistics of estimated total cholesterol. METHODS: Means, standard deviations, and correlations among the cholesterol parameters were estimated from NHANES data for metabolic syndrome (MS) and diabetic patients with all parameters uncontrolled. For simulation, distributions were fit to the data. Analyses used 1000 replications of populations of 1000. Populations were generated without correlated parameters and with correlation induced in the uncorrelated data. Estimated changes with fenofibrate, statins, and a combination were taken from the literature. Total cholesterol was approximated using HDL, plus LDL, plus 20% of triglycerides. Differences in means and ratios of variances comparing uncorrelated and correlated results were calculated for each replication. Null hypotheses were rejected when the interval the middle 95% of replications spanned did not include zero for differences and one for ratios. RESULTS: Correlations were higher for diabetic than MS patients. Despite the data's and distribution's non-normality, induced correlations were close to NHANES correlations. Correlation did not affect the summary statistics of individual parameters or the propor-tion with all parameters under control. Correlation affected results for total cholesterol, the sum of other parameters. For MS, variance of total cholesterol was less than 7% lower with uncorrelated data than with correlated data. For diabetic patients, variance of total cholesterol was more than 20% higher with uncorrelated data. Findings held for subpopulations with and without all parameters controlled after taking medication. Variance results were similar across treatments. Total cholesterol means differed primarily for MS subgroups. CONCLUSIONS: Summary statistics (particularly variance) for sums of parameters are affected by correlation in Monte Carlo simulations. Underestimated and overestimated variances increase the risk of Type I and II error respectively.
PDB23 EXTERNAL VALIDATION OF THE UKPDS OUTCOMES MODEL EQUATIONS (UKPDS 68), AND THE UKPDS RISK ENGINE EQUATIONS (UKPDS 56 AND 60) IN FORECASTING CARDIOVASCULAR OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES
PDB25 MARGINAL STRUCTURAL MODELS-AN EXPLANATION AND ILLUSTRATION
Gause D, Plauschinat C, Kahler K Novartis Pharmaceuticals, East Hanover, NJ, USA OBJECTIVES: 1) Provide a concise explanation of "inverse probability of treatment weights" (IPTWs) for estimating marginal structural models (MSM), pointing out its advantages and disadvantages to alternative methods of adjusting for covariates in observational studies, and 2) illustrate use of MSM for comparing impact of drug use on medical costs. METHODS: Confounding can be controlled by stratification or with covariates in regression. When there are many confounders adjustment using propensity scores is sometimes used but these are 1) not easily generalized with more than two comparison groups, and 2) may result in residual confounding when matching is used, and is not helpful with time dependent covariates affected by the exposures being compared. An alternative is based on modeling the "marginal" distribution of counterfactuals associated with each group (as described by Robins, Hernan, and Brumback [2000] ). This is accomplished using weights related to propensity scores. A MSM will be illustrated by comparing outpatient medical costs for patients taking diabetic drug treatments, adjusting for both baseline and subsequent time dependent diagnoses and lab data. A multinomial logit model is used to estimate each subject's conditional probability of receiving TZD, sulfonylurea, or metformin given their history of baseline and time dependent covariates. RESULTS: These predicted probabilities are basis for IPTWs used to estimate mean marginal outpatient costs for each drug group. CONCLUSIONS: Effects of confounders are broken when their associations with drug treatment groups are broken, and this can be done using MSM where the data is reweighted such that confounders have similar distributions within drug comparison groups.
